Skip to main content
Erschienen in: Clinical Pharmacokinetics 9/2016

15.03.2016 | Review Article

Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy

verfasst von: Rajendra S. Kadam, Johannes N. Van Den Anker

Erschienen in: Clinical Pharmacokinetics | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Voriconazole is a potent antifungal agent used for the treatment of invasive fungal infections caused by Aspergillus and Candida species in adult and pediatric patients. Voriconazole has a narrow therapeutic index and a large intra- and inter-individual pharmacokinetics (PK) variability. Several factors including non-linear PK, age, body weight, cytochrome P450 2C19 genotype, concomitant drugs, liver function, and food are responsible for the large variability in voriconazole PK. A combination of a narrow therapeutic index with a large PK variability results in treatment failure in many patients at clinically recommended doses. There is an urgent need to establish an optimal dosing regimen for pediatric patients <2 years of age because of a lack of recommended dosing guidelines and high (>60 %) treatment failure rates. Therapeutic drug monitoring is commonly used in clinical practice to optimize the voriconazole dosing regimens in pediatric patients, but it is associated with several practical limitations. Implementation of a PK model-guided individualized dose selection will help in reducing the PK variability and will improve therapeutic outcomes. In this review, we have summarized the covariates influencing the PK of voriconazole in adult and pediatric patients, emphasizing that the clearance of voriconazole is significantly different between adult and pediatric patients owing to developmental changes in the major clearance pathways. Moreover, we have provided the limitations of the current dosing regimens and have proposed a new dosing method using a PK model-guided dose individualization of voriconazole in pediatric patients.
Literatur
1.
Zurück zum Zitat Singhi S, Deep A. Invasive candidiasis in pediatric intensive care units. Indian J Pediatr. 2009;76(10):1033–44.PubMedCrossRef Singhi S, Deep A. Invasive candidiasis in pediatric intensive care units. Indian J Pediatr. 2009;76(10):1033–44.PubMedCrossRef
2.
Zurück zum Zitat Arendrup MC, Fisher BT, Zaoutis TE. Invasive fungal infections in the paediatric and neonatal population: diagnostics and management issues. Clin Microbiol Infect. 2009;15(7):613–24.PubMedCrossRef Arendrup MC, Fisher BT, Zaoutis TE. Invasive fungal infections in the paediatric and neonatal population: diagnostics and management issues. Clin Microbiol Infect. 2009;15(7):613–24.PubMedCrossRef
3.
Zurück zum Zitat Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21(3):240–8.PubMedCrossRef Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21(3):240–8.PubMedCrossRef
4.
Zurück zum Zitat Oren I, Paul M. Up to date epidemiology, diagnosis and management of invasive fungal infections. Clin Microbiol Infect. 2014;20(Suppl 6):1–4.PubMedCrossRef Oren I, Paul M. Up to date epidemiology, diagnosis and management of invasive fungal infections. Clin Microbiol Infect. 2014;20(Suppl 6):1–4.PubMedCrossRef
5.
Zurück zum Zitat Steinbach WJ. Epidemiology of invasive fungal infections in neonates and children. Clin Microbiol Infect. 2010;16(9):1321–7.PubMedCrossRef Steinbach WJ. Epidemiology of invasive fungal infections in neonates and children. Clin Microbiol Infect. 2010;16(9):1321–7.PubMedCrossRef
6.
Zurück zum Zitat Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. 2004;17(3):638–80.PubMedPubMedCentralCrossRef Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. 2004;17(3):638–80.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Fluckiger U, Marchetti O, Bille J, Eggimann P, Zimmerli S, Imhof A, et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly. 2006;136(29–30):447–63.PubMed Fluckiger U, Marchetti O, Bille J, Eggimann P, Zimmerli S, Imhof A, et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly. 2006;136(29–30):447–63.PubMed
8.
Zurück zum Zitat Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33(1):23–32.PubMedCrossRef Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33(1):23–32.PubMedCrossRef
9.
Zurück zum Zitat Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883–93.PubMedCrossRef Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883–93.PubMedCrossRef
10.
Zurück zum Zitat Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med. 2002;347(6):408–15.PubMedCrossRef Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med. 2002;347(6):408–15.PubMedCrossRef
11.
Zurück zum Zitat Shetty D, Giri N, Gonzalez CE, Pizzo PA, Walsh TJ. Invasive aspergillosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1997;16(2):216–21.PubMedCrossRef Shetty D, Giri N, Gonzalez CE, Pizzo PA, Walsh TJ. Invasive aspergillosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1997;16(2):216–21.PubMedCrossRef
12.
Zurück zum Zitat Steinbach WJ. Antifungal agents in children. Pediatr Clin N Am. 2005;52(3):895–915 (viii).CrossRef Steinbach WJ. Antifungal agents in children. Pediatr Clin N Am. 2005;52(3):895–915 (viii).CrossRef
13.
Zurück zum Zitat Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.PubMedCrossRef Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.PubMedCrossRef
14.
Zurück zum Zitat Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 2013;57(1):235–40.PubMedCentralCrossRef Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 2013;57(1):235–40.PubMedCentralCrossRef
15.
Zurück zum Zitat Spriet I, Cosaert K, Renard M, Uyttebroeck A, Meyts I, Proesmans M, et al. Voriconazole plasma levels in children are highly variable. Eur J Clin Microbiol Infect Dis. 2011;30(2):283–7.PubMedCrossRef Spriet I, Cosaert K, Renard M, Uyttebroeck A, Meyts I, Proesmans M, et al. Voriconazole plasma levels in children are highly variable. Eur J Clin Microbiol Infect Dis. 2011;30(2):283–7.PubMedCrossRef
16.
Zurück zum Zitat Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother. 2010;54(8):3225–32.PubMedPubMedCentralCrossRef Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother. 2010;54(8):3225–32.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Yamada T, Mino Y, Yagi T, Naito T, Kawakami J. Saturated metabolism of voriconazole N-oxidation resulting in nonlinearity of pharmacokinetics of voriconazole at clinical doses. Biol Pharm Bull. 2015;38(10):1496–503.PubMedCrossRef Yamada T, Mino Y, Yagi T, Naito T, Kawakami J. Saturated metabolism of voriconazole N-oxidation resulting in nonlinearity of pharmacokinetics of voriconazole at clinical doses. Biol Pharm Bull. 2015;38(10):1496–503.PubMedCrossRef
18.
Zurück zum Zitat Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68(6):906–15.PubMedPubMedCentralCrossRef Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68(6):906–15.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos. 2003;31(6):731–41.PubMedCrossRef Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos. 2003;31(6):731–41.PubMedCrossRef
20.
Zurück zum Zitat Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48(6):2166–72.PubMedPubMedCentralCrossRef Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48(6):2166–72.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents. 2006;27(4):274–84.PubMedCrossRef Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents. 2006;27(4):274–84.PubMedCrossRef
23.
Zurück zum Zitat Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46(8):2546–53.PubMedPubMedCentralCrossRef Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46(8):2546–53.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol. 1997;97(3):663–5.PubMedCrossRef Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol. 1997;97(3):663–5.PubMedCrossRef
25.
Zurück zum Zitat Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37(5):728–32.PubMedCrossRef Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37(5):728–32.PubMedCrossRef
26.
Zurück zum Zitat Bakleh M, Aksamit AJ, Tleyjeh IM, Marshall WF. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis. 2005;40(9):e69–71.PubMedCrossRef Bakleh M, Aksamit AJ, Tleyjeh IM, Marshall WF. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis. 2005;40(9):e69–71.PubMedCrossRef
27.
Zurück zum Zitat Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122(1):42–7.PubMedCrossRef Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122(1):42–7.PubMedCrossRef
28.
Zurück zum Zitat Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol. 2000;84(8):932–3.PubMedCrossRef Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol. 2000;84(8):932–3.PubMedCrossRef
29.
Zurück zum Zitat Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31(5):540–7.PubMedCrossRef Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31(5):540–7.PubMedCrossRef
30.
Zurück zum Zitat Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931–56.PubMedCrossRef Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931–56.PubMedCrossRef
31.
Zurück zum Zitat Upreti VV, Wahlstrom JL. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2016;56(3):266–83. Upreti VV, Wahlstrom JL. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2016;56(3):266–83.
32.
Zurück zum Zitat Hines RN. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm. 2013;452(1–2):3–7.PubMedCrossRef Hines RN. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm. 2013;452(1–2):3–7.PubMedCrossRef
33.
Zurück zum Zitat Allegaert K, van de Velde M, van den Anker J. Neonatal clinical pharmacology. Paediatr Anaesth. 2014;24(1):30–8.PubMedCrossRef Allegaert K, van de Velde M, van den Anker J. Neonatal clinical pharmacology. Paediatr Anaesth. 2014;24(1):30–8.PubMedCrossRef
34.
Zurück zum Zitat Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004;308(3):965–74.PubMedCrossRef Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004;308(3):965–74.PubMedCrossRef
35.
Zurück zum Zitat de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37(6):485–505.PubMedCrossRef de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37(6):485–505.PubMedCrossRef
36.
Zurück zum Zitat Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53(3):935–44.PubMedCrossRef Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53(3):935–44.PubMedCrossRef
37.
Zurück zum Zitat Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009;49(2):196–204.PubMedCrossRef Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009;49(2):196–204.PubMedCrossRef
38.
Zurück zum Zitat Hicks JK, Crews KR, Flynn P, Haidar CE, Daniels CC, Yang W, et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics. 2014;15(8):1065–78.PubMedPubMedCentralCrossRef Hicks JK, Crews KR, Flynn P, Haidar CE, Daniels CC, Yang W, et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics. 2014;15(8):1065–78.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Cline Pharmacol. 2010;69(3):222–30.CrossRef Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Cline Pharmacol. 2010;69(3):222–30.CrossRef
40.
Zurück zum Zitat Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009;65(3):281–5.PubMedCrossRef Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009;65(3):281–5.PubMedCrossRef
41.
Zurück zum Zitat Imamura CK, Furihata K, Okamoto S, Tanigawara Y. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. J Clin Pharmacol. 2015. doi:10.1002/jcph.605. Imamura CK, Furihata K, Okamoto S, Tanigawara Y. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. J Clin Pharmacol. 2015. doi:10.​1002/​jcph.​605.​
42.
Zurück zum Zitat Lee SJ. Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine. Front Genet. 2012;3:318.PubMed Lee SJ. Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine. Front Genet. 2012;3:318.PubMed
43.
Zurück zum Zitat Wang T, Zhu H, Sun J, Cheng X, Xie J, Dong H, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents. 2014;44(5):436–42.PubMedCrossRef Wang T, Zhu H, Sun J, Cheng X, Xie J, Dong H, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents. 2014;44(5):436–42.PubMedCrossRef
44.
Zurück zum Zitat Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, et al. Opposite effects of short-term and long-term St John’s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther. 2005;78(1):25–33.PubMedCrossRef Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, et al. Opposite effects of short-term and long-term St John’s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther. 2005;78(1):25–33.PubMedCrossRef
45.
Zurück zum Zitat Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther. 2004;75(6):587–8.PubMedCrossRef Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther. 2004;75(6):587–8.PubMedCrossRef
46.
Zurück zum Zitat Narita A, Muramatsu H, Sakaguchi H, Doisaki S, Tanaka M, Hama A, et al. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children. J Pediatr Hematol Oncol. 2013;35(5):e219–23.PubMedCrossRef Narita A, Muramatsu H, Sakaguchi H, Doisaki S, Tanaka M, Hama A, et al. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children. J Pediatr Hematol Oncol. 2013;35(5):e219–23.PubMedCrossRef
47.
Zurück zum Zitat Bruggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J. 2011;30(6):533–4.PubMed Bruggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J. 2011;30(6):533–4.PubMed
48.
Zurück zum Zitat Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54(10):4116–23.PubMedPubMedCentralCrossRef Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54(10):4116–23.PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Driscoll TA, Yu LC, Frangoul H, Krance RA, Nemecek E, Blumer J, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother. 2011;55(12):5770–9.PubMedPubMedCentralCrossRef Driscoll TA, Yu LC, Frangoul H, Krance RA, Nemecek E, Blumer J, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother. 2011;55(12):5770–9.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Neely M, Margol A, Fu X, van Guilder M, Bayard D, Schumitzky A, et al. Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrob Agents Chemother. 2015;59(6):3090–7.PubMedPubMedCentralCrossRef Neely M, Margol A, Fu X, van Guilder M, Bayard D, Schumitzky A, et al. Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrob Agents Chemother. 2015;59(6):3090–7.PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Goutelle S, Larcher R, Padoin C, Mialou V, Bleyzac N. Oral voriconazole dose in children: one size does not fit all. Clin Infect Dis. 2010;51(7):870 (author reply 1).PubMedCrossRef Goutelle S, Larcher R, Padoin C, Mialou V, Bleyzac N. Oral voriconazole dose in children: one size does not fit all. Clin Infect Dis. 2010;51(7):870 (author reply 1).PubMedCrossRef
52.
Zurück zum Zitat Liu P, Mould DR. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob Agents Chemother. 2014;58(8):4718–26.PubMedPubMedCentralCrossRef Liu P, Mould DR. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob Agents Chemother. 2014;58(8):4718–26.PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Hope WW. Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemotherapy. 2012;56(1):526–31.CrossRef Hope WW. Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemotherapy. 2012;56(1):526–31.CrossRef
54.
Zurück zum Zitat Wang T, Chen S, Sun J, Cai J, Cheng X, Dong H, et al. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. J Antimicrob Chem. 2014;69(2):463–70.CrossRef Wang T, Chen S, Sun J, Cai J, Cheng X, Dong H, et al. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. J Antimicrob Chem. 2014;69(2):463–70.CrossRef
55.
Zurück zum Zitat Bruggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441–58.PubMedCrossRef Bruggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441–58.PubMedCrossRef
56.
Zurück zum Zitat Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br J Clin Pharmacol. 2003;56(S1):145–50. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br J Clin Pharmacol. 2003;56(S1):145–50.
57.
Zurück zum Zitat Nivoix Y, Leveque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet. 2008;47(12):779–92.PubMedCrossRef Nivoix Y, Leveque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet. 2008;47(12):779–92.PubMedCrossRef
58.
Zurück zum Zitat Gupta A, Unadkat JD, Mao Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci. 2007;96(12):3226–35.PubMedCrossRef Gupta A, Unadkat JD, Mao Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci. 2007;96(12):3226–35.PubMedCrossRef
59.
Zurück zum Zitat Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47(10):3165–9.PubMedPubMedCentralCrossRef Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47(10):3165–9.PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Chen J, Chan C, Colantonio D, Seto W. Therapeutic drug monitoring of voriconazole in children. Ther Drug Monit. 2012;34(1):77–84.PubMedCrossRef Chen J, Chan C, Colantonio D, Seto W. Therapeutic drug monitoring of voriconazole in children. Ther Drug Monit. 2012;34(1):77–84.PubMedCrossRef
61.
Zurück zum Zitat Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect. 2010;16(7):927–33.PubMedCrossRef Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect. 2010;16(7):927–33.PubMedCrossRef
62.
Zurück zum Zitat Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol. 2009;89(5):592–9.PubMedCrossRef Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol. 2009;89(5):592–9.PubMedCrossRef
63.
Zurück zum Zitat Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11.PubMedCrossRef Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11.PubMedCrossRef
64.
Zurück zum Zitat Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50(1):27–36.PubMedPubMedCentralCrossRef Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50(1):27–36.PubMedPubMedCentralCrossRef
65.
Zurück zum Zitat Choi SH, Lee SY, Hwang JY, Lee SH, Yoo KH, Sung KW, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer. 2013;60(1):82–7.PubMedCrossRef Choi SH, Lee SY, Hwang JY, Lee SH, Yoo KH, Sung KW, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer. 2013;60(1):82–7.PubMedCrossRef
66.
Zurück zum Zitat Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46(2):235–43. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46(2):235–43.
67.
Zurück zum Zitat Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563–71.CrossRef Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563–71.CrossRef
68.
Zurück zum Zitat Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukamizu T, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents. 2009;34(1):91–4.PubMedCrossRef Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukamizu T, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents. 2009;34(1):91–4.PubMedCrossRef
69.
Zurück zum Zitat Celik IH, Demirel G, Oguz SS, Uras N, Erdeve O, Dilmen U. Compassionate use of voriconazole in newborn infants diagnosed with severe invasive fungal sepsis. Eur Rev Med Pharmacol Sci. 2013;17:729–34.PubMed Celik IH, Demirel G, Oguz SS, Uras N, Erdeve O, Dilmen U. Compassionate use of voriconazole in newborn infants diagnosed with severe invasive fungal sepsis. Eur Rev Med Pharmacol Sci. 2013;17:729–34.PubMed
70.
Zurück zum Zitat Kohli V, Taneja V, Sachdev P, Joshi R. Voriconazole in newborns. Indian Pediatr. 2008;45(3):236–8.PubMed Kohli V, Taneja V, Sachdev P, Joshi R. Voriconazole in newborns. Indian Pediatr. 2008;45(3):236–8.PubMed
71.
Zurück zum Zitat Frankenbusch K, Eifinger F, Kribs A, Rengelshauseu J, Roth B. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight. J Perinatol. 2006;26(8):511–4.PubMedCrossRef Frankenbusch K, Eifinger F, Kribs A, Rengelshauseu J, Roth B. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight. J Perinatol. 2006;26(8):511–4.PubMedCrossRef
72.
Zurück zum Zitat von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol. 2006;6:6.CrossRef von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol. 2006;6:6.CrossRef
73.
Zurück zum Zitat Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55(8):1080–7.PubMedCrossRef Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55(8):1080–7.PubMedCrossRef
74.
Zurück zum Zitat Elewa H, El-Mekaty E, El-Bardissy A, Ensom MH, Wilby KJ. Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: a critical review. Clin Pharmacokinet. 2015;54(12):1223–35. Elewa H, El-Mekaty E, El-Bardissy A, Ensom MH, Wilby KJ. Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: a critical review. Clin Pharmacokinet. 2015;54(12):1223–35.
75.
Zurück zum Zitat Gage R, Stopher DA. A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal. 1998;17(8):1449–53.PubMedCrossRef Gage R, Stopher DA. A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal. 1998;17(8):1449–53.PubMedCrossRef
76.
Zurück zum Zitat Perea S, Pennick GJ, Modak A, Fothergill AW, Sutton DA, Sheehan DJ, et al. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother. 2000;44(5):1209–13.PubMedPubMedCentralCrossRef Perea S, Pennick GJ, Modak A, Fothergill AW, Sutton DA, Sheehan DJ, et al. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother. 2000;44(5):1209–13.PubMedPubMedCentralCrossRef
77.
Zurück zum Zitat Lin D, Li G, Chen L. Determination of voriconazole in human plasma by HPLC-ESI-MS and application to pharmacokinetic study. J Chromatogr Sci. 2013;51(6):485–9.PubMedCrossRef Lin D, Li G, Chen L. Determination of voriconazole in human plasma by HPLC-ESI-MS and application to pharmacokinetic study. J Chromatogr Sci. 2013;51(6):485–9.PubMedCrossRef
78.
Zurück zum Zitat Gogtay NJ, Kshirsagar NA, Dalvi SS. Therapeutic drug monitoring in a developing country: an overview. Br J Clin Pharmacol. 2001;52(Suppl 1):103S–8S.PubMedPubMedCentralCrossRef Gogtay NJ, Kshirsagar NA, Dalvi SS. Therapeutic drug monitoring in a developing country: an overview. Br J Clin Pharmacol. 2001;52(Suppl 1):103S–8S.PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Dolton MJ, Mikus G, Weiss J, Ray JE, McLachlan AJ. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J Antimicrob Chem. 2014;69(6):1633–41.CrossRef Dolton MJ, Mikus G, Weiss J, Ray JE, McLachlan AJ. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J Antimicrob Chem. 2014;69(6):1633–41.CrossRef
81.
Zurück zum Zitat Sandstrom M, Karlsson MO, Ljungman P, Hassan Z, Jonsson EN, Nilsson C, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transpl. 2001;28(7):657–64.CrossRef Sandstrom M, Karlsson MO, Ljungman P, Hassan Z, Jonsson EN, Nilsson C, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transpl. 2001;28(7):657–64.CrossRef
82.
Zurück zum Zitat Wallin JE, Friberg LE, Fasth A, Staatz CE. Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. Ther Drug Monit. 2009;31(4):457–66.PubMedCrossRef Wallin JE, Friberg LE, Fasth A, Staatz CE. Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. Ther Drug Monit. 2009;31(4):457–66.PubMedCrossRef
83.
Zurück zum Zitat Dombrowsky E, Jayaraman B, Narayan M, Barrett JS. Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit. 2011;33(1):99–107.PubMedPubMedCentralCrossRef Dombrowsky E, Jayaraman B, Narayan M, Barrett JS. Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit. 2011;33(1):99–107.PubMedPubMedCentralCrossRef
84.
Zurück zum Zitat Wright DF, Duffull SB. Development of a bayesian forecasting method for warfarin dose individualization. Pharm Res. 2011;28(5):1100–11.PubMedCrossRef Wright DF, Duffull SB. Development of a bayesian forecasting method for warfarin dose individualization. Pharm Res. 2011;28(5):1100–11.PubMedCrossRef
85.
Zurück zum Zitat Wright DF, Duffull SB. A Bayesian dose-individualization method for warfarin. Clin Pharmacokinet. 2013;52(1):59–68.PubMedCrossRef Wright DF, Duffull SB. A Bayesian dose-individualization method for warfarin. Clin Pharmacokinet. 2013;52(1):59–68.PubMedCrossRef
88.
Zurück zum Zitat Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012;56(6):3032–42.PubMedPubMedCentralCrossRef Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012;56(6):3032–42.PubMedPubMedCentralCrossRef
89.
Zurück zum Zitat Chung H, Lee H, Han H, An H, Lim KS, Lee Y, et al. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles. Drug Design Dev Ther. 2015;9:2609–16.CrossRef Chung H, Lee H, Han H, An H, Lim KS, Lee Y, et al. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles. Drug Design Dev Ther. 2015;9:2609–16.CrossRef
90.
Zurück zum Zitat Lee S, Kim BH, Nam WS, Yoon SH, Cho JY, Shin SG, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2012;52(2):195–203.PubMedCrossRef Lee S, Kim BH, Nam WS, Yoon SH, Cho JY, Shin SG, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2012;52(2):195–203.PubMedCrossRef
91.
Zurück zum Zitat Shi HY, Yan J, Zhu WH, Yang GP, Tan ZR, Wu WH, et al. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. Eur J Clin Pharmacol. 2010;66(11):1131–6.PubMedPubMedCentralCrossRef Shi HY, Yan J, Zhu WH, Yang GP, Tan ZR, Wu WH, et al. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. Eur J Clin Pharmacol. 2010;66(11):1131–6.PubMedPubMedCentralCrossRef
92.
Zurück zum Zitat Levin MD, den Hollander JG, van der Holt B, Rijnders BJ, van Vliet M, Sonneveld P, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chem. 2007;60(5):1104–7.CrossRef Levin MD, den Hollander JG, van der Holt B, Rijnders BJ, van Vliet M, Sonneveld P, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chem. 2007;60(5):1104–7.CrossRef
Metadaten
Titel
Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy
verfasst von
Rajendra S. Kadam
Johannes N. Van Den Anker
Publikationsdatum
15.03.2016
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 9/2016
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-016-0379-2

Weitere Artikel der Ausgabe 9/2016

Clinical Pharmacokinetics 9/2016 Zur Ausgabe